Castleview Partners’s GSK GSK Stock Holding History

Castleview Partners’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-8	Closed	-$281	–	684
2022 Q4	$281	Buy	+8	New	+$266	﹤0.01%	604

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Castleview Partners's GSK Position: Q1 2023 in Review

Castleview Partners sold out of GSK (GSK) in Q1 2023, closing a stake of 8 shares — an estimated $281 sold.

Castleview Partners first reported a position in GSK in Q4 2022 and held it in 1 quarter. The position peaked at $281 in Q4 2022. 809 funds tracked by Wall St. Rank hold GSK as of Q1 2023.

Castleview Partners reported no remaining GSK position as of Q1 2023 after selling out during the quarter.
Castleview Partners sold 8 GSK shares in Q1 2023, an estimated $281.
Castleview Partners first reported a position in GSK in Q4 2022 and held it in 1 quarter.
Castleview Partners's GSK position peaked at $281 in Q4 2022.
809 funds tracked by Wall St. Rank held GSK as of Q1 2023.

Based on Castleview Partners's 13F filing for Q1 2023, filed 16 May 2023.